Dr. Yongsheng Wang 王永胜
Chief Physician, Research Professor
Department of Breast Surgery I, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Breast-conserving therapy, sentinel lymph node biopsy as an alternative to axillary dissection, minimally invasive diagnosis of breast lesions, and minimally invasive breast-conserving treatment.
Dr. Wang holds a medical doctorate and serves as Professor and Chief of General Surgery at Shandong Cancer Hospital. Trained as a visiting scholar at University Hospital of Wales, UK (1998–1999). Research focuses on sentinel lymph node biopsy and breast-conserving therapy. Authored over 200 papers, including 70 SCI-indexed, and edited multiple textbooks.
Professional roles
- Vice Chair, Breast Cancer Professional Committee, China Anti-Cancer Association
- Vice Chair, International Medical Exchange Branch, China Anti-Cancer Association
- Member, Breast Cancer Group, Oncology Branch, Chinese Medical Association
- Vice Chair, Breast Surgery Committee, Tumor Physician Branch, Chinese Medical Doctor Association
Name order: in Chinese the family name comes first (Wang Yongsheng). Papers usually list the name as Yongsheng Wang or Wang Y.
Selected publications
153 papers on PubMed matched by name and affiliation; 61 as first or senior author since 2016. Most recent first- or senior-author papers:
- Signal Transduct Target Ther, 2026 (senior author): Carbon nanoparticle-Fe (II) complex for ferroptosis therapy in refractory solid tumors: a phase I trial. PubMed 42816483
- MedComm (2020), 2026 (first author): Clinical Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy for Triple-Negative Breast Cancer and Tumor Immune Microenvironment Analysis: A Prospective-Retrospective Cohort Study. PubMed 42609520
- BMC Cancer, 2026 (senior author): Patient-reported outcomes of adjuvant therapy with CDK4/6 inhibitors for HR+/HER2- early breast cancer: a retrospective cohort study. PubMed 41965632
- Int J Surg, 2026 (senior author): Efficacy, safety, and biomarkers of neoadjuvant trastuzumab and pertuzumab combined with chemotherapy in Chinese patients with HER2-positive breast cancer: a multicenter retrospective cohort study. PubMed 41056055
- J Natl Cancer Cent, 2025 (first author): Real-world effectiveness of goserelin 10.8-mg compared to goserelin 3.6-mg in premenopausal and perimenopausal Chinese patients with hormone receptor positive breast cancer: a cohort study. PubMed 40814439
- J Breast Cancer, 2025 (senior author): Multidisciplinary Team Intervention: Catalysts for Changing Prognosis in Advanced Breast Cancer. PubMed 40432353
- Oncologist, 2025 (senior author): Phase I trial of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors. PubMed 40586764
- Int J Surg, 2025 (senior author): Identification of biomarkers of shrinkage modes after neoadjuvant therapy in HER-2 positive breast cancer. PubMed 40143733
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion